TRCT
PSTV

Tower Research Capital (TRC)’s Plus Therapeutics PSTV Stock Holding History

Tower Research Capital (TRC)’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-141
Closed -$2.41K – 5491
2025
Q3 		$2.41K Sell
141
-101
-42% -$1.24K ﹤0.01% 4634
2025
Q2 		$2.1K Sell
242
-65
-21% -$850 ﹤0.01% 4700
2025
Q1 		$7.29K Buy
307
+116
+61% +$3.24K ﹤0.01% 3964
2024
Q4 		$5.5K Buy
191
+43
+29% +$1.38K ﹤0.01% 4279
2024
Q3 		$5.42K Sell
148
-19
-11% -$750 ﹤0.01% 4278
2024
Q2 		$6.15K Buy
167
+14
+9% +$687 ﹤0.01% 4613
2024
Q1 		$6.91K Buy
153
+130
+565% +$6.29K ﹤0.01% 4296
2023
Q4 		$1K Sell
23
-35
-60% -$1.4K ﹤0.01% 5464
2023
Q3 		$1.94K Sell
58
-131
-69% -$7.03K ﹤0.01% 5235
2023
Q2 		$9.56K Buy
189
+165
+688% +$15.4K ﹤0.01% 4256
2023
Q1 		$3K Hold
24
– – ﹤0.01% 5230
2022
Q4 		$3K Sell
24
-2
-8% -$318 ﹤0.01% 5220
2022
Q3 		$4K Sell
26
-28
-52% -$6.25K ﹤0.01% 5283
2022
Q2 		$11K Buy
54
+29
+116% +$7.24K ﹤0.01% 4386
2022
Q1 		$9K Buy
+25
New +$9.51K ﹤0.01% 4477
2021
Q4 		– Hold
0
– – – 6478
2021
Q2 		– Sell
-5
Closed -$5K – 5760
2021
Q1 		$5K Buy
5
+4
+400% +$4.05K ﹤0.01% 4687
2020
Q4 		$1K Sell
1
-2
-67% -$1.71K ﹤0.01% 5025
2020
Q3 		$3K Buy
+3
New +$2.91K ﹤0.01% 4517
2016
Q3 		– Hold
0
– -$2K – 4265
2016
Q2 		– Hold
0
– – – 3942
2016
Q1 		– Hold
0
– – – 4759
2015
Q4 		– Hold
0
– – – 4934
2015
Q3 		– Hold
0
– -$2K – 4610
2015
Q2 		– Hold
0
– – – 3777
2014
Q4 		– Hold
0
– -$25K – 4555
2014
Q3 		– Hold
0
– – – 2124
2014
Q2 		– Hold
0
– – – 3735
2014
Q1 		– Hold
0
– – – 3895

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
L1 Global Manager Melbourne $149M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Tower Research Capital (TRC)'s PSTV Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of Plus Therapeutics (PSTV) in Q4 2025, closing a stake of 141 shares — an estimated $2.41K sold.

Tower Research Capital (TRC) first reported a position in PSTV in Q3 2020 and held it in 18 quarters. The position peaked at $11K in Q2 2022. 25 funds tracked by Wall St. Rank hold PSTV as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining Plus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 141 Plus Therapeutics shares in Q4 2025, an estimated $2.41K.
  • Tower Research Capital (TRC) first reported a position in Plus Therapeutics in Q3 2020 and held it in 18 quarters.
  • Tower Research Capital (TRC)'s Plus Therapeutics position peaked at $11K in Q2 2022.
  • 25 funds tracked by Wall St. Rank held Plus Therapeutics as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.